Baird raises Hinge Health price target to $65
Baird analyst Vikram Kesavabhotla maintained a Neutral rating on Hinge Health and raised the price target to $65 from $55.
*this image is generated using AI for illustrative purposes only.
Baird analyst Vikram Kesavabhotla has maintained a Neutral rating on Hinge Health while increasing the stock's price target. The new target of $65 represents an increase from the previous estimate of $55.
Rating and Price Action
The decision to raise the price target comes despite the continued Neutral stance on the company. The revised target suggests potential upside from current trading levels, though the analyst remains cautious regarding the stock's overall risk-reward profile.
| Metric | Value |
|---|---|
| Rating | Neutral |
| Previous Price Target | $55 |
| New Price Target | $65 |
What specific factors drove the decision to raise the price target despite maintaining a Neutral rating?
How might Hinge Health's recent performance influence future analyst ratings?
What are the key risks that could prevent the stock from reaching the new $65 target?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
